All In Biotech

Drug Trial Radar · NCT03563157

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy

Last checked: Nov 20, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

2

Actual

Start

Sep 28, 2018

Primary completion

Apr 21, 2019

Study completion Aug 21, 2019

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Jun 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.

Conditions

  • Colorectal Cancer Metastatic
  • mCRC

Interventions

  • Aldoxorubicin HydrochlorideBiological

    Aldoxorubicin Hydrochloride HCI

  • ALT-803Biological

    Recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1\]

  • ETBX-011Biological

    Ad5 \[E1-, E2b-\]-CEA

  • ETBX-021Biological

    Ad5 \[E1-, E2b-\]-\[HER2\]

  • ETBX-051Biological

    Ad5 \[E1-, E2b-\]-Brachyury

  • ETBX-061Biological

    Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]

  • GI-4000Biological

    RAS yeast

  • GI-6207Biological

    CEA yeast

  • GI-6301Biological

    Brachyury yeast

  • haNKBiological

    haNK™, NK-92 \[CD16.158V, ER IL-2\]

  • AvelumabDrug

    BAVENCIO® injection

  • CapecitabineDrug

    XELODA® tablets

  • CetuximabDrug

    ERBITUX® injection

  • CyclophosphamideDrug

    Cyclophosphamide Capsules

  • 5-FluorouracilDrug

    5-FU; Fluorouracil Injection

  • LeucovorinDrug

    Leucovorin Calcium

  • Nab-paclitaxelDrug

    ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]

  • OxaliplatinDrug

    ELOXATIN® injection

  • RegorafenibDrug

    STIVARGA® tablets

  • SBRTProcedure

    Stereotactic body radiation therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: 30 days after last dose, up to 6 months or until they experience confirmed progressive disease or unacceptable toxicity, withdrawn consent, or if the Investigator feels it is no longer in their best interest.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.